Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Neurochemistry

• Publication date

  1999-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1471-4159.1999.0720682.xPMID 9930741
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic or pharmacological inactivation of the dopamine D1 receptor differentially alters the expression of regulator of G‐protein signalling (Rgs) transcripts

  2006cited by this paper
• Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion

  2005cited by this paper
• Selective D-1 dopamine receptor agonist treatment of parkinson's disease

  2005cited by this paper
• Dopamine D1-Like Receptor Activation Excites Rat Striatal Large Aspiny Neurons In Vitro

  1998cited by this paper
• Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.

  1997cited by this paper
• The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors.

  1997cited by this paper
• Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

  1997influential reference
• Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat.

  1997cited by this paper
• Synaptic Connections Between Spiny Neurons of the Direct and Indirect Pathways in the Neostriatum of the Rat: Evidence from Dopamine Receptor and Neuropeptide Immunostaining

  1996cited by this paper
• Chronic Dizocilpine Maleate (MK‐801) Treatment Suppresses the Effects of Nigrostriatal Dopamine Deafferentation on Enkephalin but not on Substance P Expression in the Rat Striatum

  1996cited by this paper
• Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons

  1996cited by this paper
• Bilateral 6‐Hydroxydopamine‐induced Lesion of the Nigrostriatal Dopamine Pathway Reproduces the Effects of Unilateral Lesion on Substance P but not on Enkephalin Expression in Rat Basal Ganglia

  1996cited by this paper
• Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates.

  1996influential reference
• Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.

  1996cited by this paper
• D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine

  1996cited by this paper
• Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.

  1996cited by this paper
• Dyskinesia and wearing‐off following dopamine D1 agonist treatment in drug‐naive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned primates

  1996cited by this paper
• Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetamine-treated rats.

  1996cited by this paper
• Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys

  1996cited by this paper
• L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.

  1995cited by this paper
• Is striatal dopaminergic receptor imbalance responsible for levodopa‐induced dyskinesia?

  1995cited by this paper
• An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria.

  1995cited by this paper
• Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum.

  1995influential reference
• Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat.

  1995influential reference
• Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease.

  1995cited by this paper
• Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum.

  1995influential reference
• D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAS in distinct neuronal populations of the dorsal and ventral striatum

  1995cited by this paper
• D2-Family receptor distribution in human postmortem tissue: an autoradiographic study

  1995cited by this paper
• Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion.

  1994cited by this paper
• Prefrontal Corticostriatal Afferents Maintain Increased Enkephalin Gene Expression in the Dopamine‐denervated Rat Striatum

  1994cited by this paper
• Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys

  1994cited by this paper
• On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.

  1994cited by this paper
• Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors

  1993cited by this paper
• Dopamine receptors in the basal ganglia: Relevance to parkinson's disease

  1993cited by this paper
• A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia.

  1992cited by this paper
• Molecular biology of dopamine receptors.

  1992cited by this paper
• Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.

  1992cited by this paper
• Development of high‐affinity choline transport sites in rat forebrain: A quantitative autoradiography study with [3H]hemicholinium‐3

  1992cited by this paper
• Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.

  1992cited by this paper
• Proenkephalin mRNA levels in rat striatum are increased and decreased, respectively, by selective D2 and D1 dopamine receptor antagonists.

  1991influential reference
• Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.

  1991influential reference
• Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: correlation with degree of parkinsonian symptoms.

  1991cited by this paper
• Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.

  1991cited by this paper
• Met‐enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration

  1990cited by this paper
• D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

  1990influential reference
• Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.

  1990influential reference
• Extrinsic connections of the basal ganglia.

  1990cited by this paper
• Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization

  1990cited by this paper
• The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones.

  1990cited by this paper
• Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy.

  1990cited by this paper
• Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 dopamine receptors.

  1989cited by this paper
• Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1989cited by this paper
• Hemicholinium-3 binding sites in rat brain: a quantitative autoradiographic study.

  1989cited by this paper
• Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys.

  1989cited by this paper
• Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment.

  1988cited by this paper
• [3H]SCH 23390 binding to D1 dopamine receptors in the basal ganglia of the cat and primate: delineation of striosomal compartments and pallidal and nigral subdivisions.

  1988cited by this paper
• Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D1 and D2 antagonists.

  1988cited by this paper
• Comparative distribution of dopamine D‐1 and D‐2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys

  1987cited by this paper
• Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions.

  1987cited by this paper
• Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.

  1986cited by this paper
• Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

  1986cited by this paper
• Reduction of striatal dopaminergic neurotransmission elevates striatal proenkephalin mRNA.

  1986cited by this paper
• A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China.

  1985cited by this paper
• Immunocytochemical Studies of Substance P and Met‐Enkephalin in the Basal Ganglia and Substantia Nigra in Huntington's, Parkinson's and Alzheimer's Diseases

  1985cited by this paper
• A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)

  1984cited by this paper
• A stereotaxic atlas of the brain of the cynomolgus monkey

  1984cited by this paper
• Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains.

  1983cited by this paper
• Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA

  1982cited by this paper

• Modeling Parkinson's Disease in Primates.

  2024cites this paper
• Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease

  2022cites this paper
• µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease

  2020cites this paper
• m Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson ’ s Disease

  2020cites this paper
• Sedative drugs modulate the neuronal activity in the subthalamic nucleus of parkinsonian patients

  2020cites this paper
• Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey

  2018influential citation
• Regulation of Dopamine-Dependent Behaviors by G Protein-Coupled Receptor Kinases

  2016cites this paper
• G protein-coupled receptor kinases as regulators of dopamine receptor functions.

  2016cites this paper
• Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

  2015cites this paper
• L'impact de la surexpression de pré-enképhaline striatale sur la dyskinésie induite par la L-DOPA dans la maladie de Parkinson

  2015cites this paper
• The Opioid System in Levodopa-Induced Dyskinesia

  2014cites this paper
• The effect of striatal pre‐enkephalin overexpression in the basal ganglia of the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson's disease

  2014cites this paper
• Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.

  2014cites this paper
• Multifunctional approach of L-Dopa induced dyskinesia pathophysiology in Parkinson’s disease : from the striatum to the whole brain

  2014cites this paper
• Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.

  2014cites this paper
• Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia.

  2014cites this paper
• Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role

  2013cites this paper
• Études de la subthalamotomie comme traitement des dyskinésies chez le primate parkinsonien

  2013cites this paper
• Modeling Parkinson's disease in primates: The MPTP model.

  2012cites this paper
• Gene Therapy for Parkinson’s: Disease from Bench to Bedside

  2012cites this paper
• Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson’s disease

  2011cites this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cites this paper
• Changes in dynorphin immunoreactivity but unaltered density of enkephalin immunoreactive neurons in basal ganglia nuclei of genetically dystonic hamsters

  2011cites this paper
• Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.

  2010cites this paper
• Lentiviral Overexpression of GRK6 Alleviates l-Dopa–Induced Dyskinesia in Experimental Parkinson’s Disease

  2010cites this paper
• Compensatory Mechanisms in Experimental and Human Parkinsonism: Potential for New Therapies Chapter 37

  2010cites this paper
• Characterisation of substance P and transient receptor potential melastatin channel messenger RNA and protein expression in acute and chronic neurological disorders.

  2010cites this paper
• Basal Ganglia Circuits Underlying the Pathophysiology of Levodopa-Induced Dyskinesia

  2010influential citation
• Dopamine Receptors and the Treatment of Parkinson's Disease

  2010cites this paper
• From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.

  2010cites this paper
• Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.

  2010cites this paper
• Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys

  2009cites this paper
• Effects of Opioid Antagonists on l-DOPA-Induced Dyskinesia in Parkinson's Disease

  2009cites this paper
• Compensatory Mechanisms in Experimental and Human Parkinsonism

  2009cites this paper
• Molecular basis of L-DOPA-induced dyskinesia : Studies on striatal signaling

  2009cites this paper
• Neuroprotection for Parkinson's Disease

  2008cites this paper
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Mammalian Models of Parkinson's Disease: Potential Uses and Misuses of Acute, Sub-acute, and Chronic Models

  2008cites this paper
• The basal ganglia in Parkinson's disease: Current concepts and unexplained observations

  2008cites this paper
• Pre‐synaptic dopaminergic compensation after moderate nigrostriatal damage in non‐human primates

  2008cites this paper
• Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities

  2008cites this paper
• Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.

  2008cites this paper
• Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease

  2007cites this paper
• Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

  2007cites this paper
• Concomitant short‐ and long‐duration response to levodopa in the 6‐OHDA‐lesioned rat: a behavioural and molecular study

  2007cites this paper
• Neurochemistry of Parkinson's disease.

  2007influential citation
• Motor deficits and altered striatal gene expression in aphakia (ak) mice.

  2007cites this paper
• Dyskinesias and Neural Grafting in Parkinson's Disease

  2006cites this paper
• What has been learnt from study of dopamine receptors in Parkinson's disease?

  2006cites this paper
• Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin

  2006cites this paper
• Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease

  2006cites this paper
• ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.

  2006cites this paper
• Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: Effect on adenosine A2A receptors

  2006cites this paper
• Modifications neurochimiques au sein des ganglions de la base et comportements moteurs associés lors d'une stimulation électrique du noyau subthalamique chez le rat hémiparkinsonien ou de la mise en place de la dénervation dopaminergique chez le singe

  2006cites this paper
• Opioids and motor complications in Parkinson's disease.

  2006cites this paper
• Phenotype of Striatofugal Medium Spiny Neurons in Parkinsonian and Dyskinetic Nonhuman Primates: A Call for a Reappraisal of the Functional Organization of the Basal Ganglia

  2006cites this paper
• How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?

  2006cites this paper
• Pathophysiology of motor fluctuations in Parkinson's disease

  2005cites this paper
• Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.

  2005cites this paper
• Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.

  2005cites this paper
• Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective.

  2005cites this paper
• Regulation of striatal preproenkephalin mRNA levels in MPTP‐lesioned mice treated with estradiol

  2005cites this paper
• Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.

  2005cites this paper
• Chronic estrogenic drug treatment increases preproenkephalin mRNA levels in the rat striatum and nucleus accumbens.

  2005cites this paper
• Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.

  2004cites this paper
• Pathogenesis of Motor Response Complications in Parkinson’s Disease: “Mere Conjectural Suggestions” and Beyond

  2004cites this paper
• Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms.

  2004cites this paper
• Striatal preprotachykinin gene expression reflects parkinsonian signs

  2004cites this paper
• The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys.

  2004cites this paper
• Levodopa in the treatment of Parkinson's disease: Current controversies

  2004cites this paper
• Altered expression of preproenkephalin and prodynorphin mRNA in a genetic model of paroxysmal dystonia.

  2004cites this paper
• COMT inhibitors in Parkinson’s disease

  2004cites this paper
• Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

  2003cites this paper
• Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.

  2003cites this paper
• New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.

  2003cites this paper
• Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.

  2003cites this paper
• Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei.

  2003cites this paper
• [Pathophysiology and therapy of L-Dopa-induced dyskinesia].

  2003cites this paper
• Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.

  2003cites this paper
• The MPTP-treated primate as a model of motor complications in PD

  2003cites this paper
• Responses to Partial Dopaminergic Lesion: Evidence for Compensatory Sprouting from the Ventral Striatum

  2002cites this paper
• [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].

  2002cites this paper
• [Dopaminergic receptors: structural features and functional implications].

  2002cites this paper
• Possible role of nondopaminergic drugs on levodopa-induced dyskinesias in Parkinson’s disease

  2002cites this paper
• The Role of Opioid Receptors in L-Dopa Induced Dyskinesia

  2002cites this paper
• Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine‐denervated rats

  2002cites this paper
• Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation

  2002cites this paper
• Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain.

  2002cites this paper
• Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey.

  2002cites this paper
• Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.

  2002cites this paper
• Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats.

  2002cites this paper
• Increase of Preproenkephalin mRNA Levels in the Putamen of Parkinson Disease Patients with Levodopa‐Induced Dyskinesias

  2002cites this paper
• Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.

  2001cites this paper
• Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies

  2001cites this paper
• Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.

  2001cites this paper
• Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.

  2001cites this paper
• Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.

  2001cites this paper
• Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

  2001cites this paper
• Expression of Striatal Preprotachykinin mRNA in Symptomatic and Asymptomatic 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Exposed Monkeys Is Related to Parkinsonian Motor Signs

  2001influential citation
• Striatal Responses to Partial Dopaminergic Lesion: Evidence for Compensatory Sprouting

  2000cites this paper
• Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum

  2000cites this paper